July 1, 2022

ACN News

Area Control Network News | Breaking News

Sputnik V peer reviewed

Sputnik V (Gam-Covid-Vac)

2 doses, 3 weeks apart

Muscle injection

Freezer storage

Developing an alternative formulation that can be refrigerated

Gamaleya Research Institute (Ministry of Health)

Combination of two adenoviruses called Ad5 and Ad26

August 11th President Putin announced approval

Before phase 3 trials had started

November, Russian government began offering Sputnik V within Russia

Widespread hesitancy

Phase 3, Russia, Belarus, UAE, Venezuela, India

Gamaleya Institute joined forces in December with the AstraZeneca

AstraZeneca / Gamaleya combination started Phase 1 trial on Dec. 24

Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00234-8/fulltext

Background

A heterologous recombinant adenovirus

Phase 2 results,

showed a good safety profile and induced strong humoral and cellular immune responses

Interim analysis of this phase 3 trial
Methods

Randomised, double-blind, placebo-controlled, phase 3 trial

25 hospitals and polyclinics in Moscow

Participants at least 18 years, with negative PCR and IgG and IgM tests

Randomly assigned (3:1) to receive vaccine or placebo

Two shots, 21 days apart

First dose, rAd26

Second dose, rAd5),

Both vectors carrying the gene for the full-length SARS-CoV-2 glycoprotein S

Outcome recorded 21 days after second shot (vaccine or placebo)

Finding

Sept 7 to Nov 24, 2020

N = 21 977

Randomly assigned

Vaccine group, n = 16 501

Placebo group, n = 5476

N = 19 866 received two doses of vaccine or placebo and were included

(2,144 participants older than 60 years, 1,611 in the vaccine group and 533 in the placebo group)

Primary outcome analysis

Included all participants who had received at least two doses at the time of database lock

Vaccine group, n = 14,964

16 (0·1%) confirmed COVID infections

No cases of moderate or severe COVID-19 confirmed at least 21 days after dose 1

Placebo group, n = 4,902

62 (1·3%) confirmed COVID infections

20 cases of moderate or severe COVID-19 confirmed at least 21 days after dose 1

Efficacy

91·6%

Vaccine efficacy was 91·8 in participants older than 60 years

Interim immunogenicity

Vaccine group

RBD-specific IgG detected in 336 (98%) of 342 samples

Seroconversion rate of 98·25%

Higher levels of interferon-gamma

(secreted by activated T helper lymphocytes, T cytotoxic lymphocytes, B lymphocytes and NKs)

Significantly higher levels of IFN-γ secretion upon antigen restimulation

Placebo group

RBD-specific IgG was detected in 17 (15%) of 114 samples

Seroconversion rate of 14·91%

(p less than 0·0001 vs the vaccine group)

Adverse events

Grade 1

7485 [94·0%] of 7966 total events

Serous adverse events

Vaccine group

45 (0·3%) of 16, 427

Placebo group

23 (0·4%) of 5435

None were considered associated with vaccination

Four deaths were reported during the study

Vaccine group

Three (less than 0·1%) of 16 427

Placebo group

One (less than 0·1%) of 5435

None of which were considered related to the vaccine

Interpretation

This interim analysis of the phase 3 trial of Gam-COVID-Vac showed 91·6% efficacy against COVID-19 and was well tolerated in a large cohort

Source: Dr. John Campbell

Hits: 0

RSS Domain names for sale

World News

Global agricultural production is already being affected by climate change. From plant growth to crop yields, our food security is being challenged on multiple fronts,...

Following the success of its vaccine passport, the Digital COVID Certificate, the EU is investing more into digital health with the European Health Data Space....

Catch up with the most important stories from around Europe and beyond - latest news, breaking news, World, Business, Entertainment, Politics, Culture, Travel. READ MORE...

A break from bad news anxiety: here are five stories about what is going well in the world. ---------------Content of this video----------------- 0:00 - Intro...

Euronews takes a look at some of the hottest cultural events in Europe at the moment. READ MORE : https://www.euronews.com/2022/07/01/art-fashion-and-film-3-european-cultural-events-you-need-to-know-about-this-weekend Subscribe to our channel: https://www.youtube.com/c/euronews?sub_confirmation=1...

Climate activists in London and Glasgow have glued themselves to famous pieces of art to call for an end to new fossil fuel projects in...

A group of "watchdog moms" are trying to keep children safe by exposing the dangers on the platform. READ MORE : https://www.euronews.com/2022/07/01/these-moms-on-tiktok-are-raising-awareness-around-child-safety-online Subscribe to our...

Many European countries are experiencing a surge in new COVID-19 infections, with the more transmissible Omicron subvariant BA.5 spreading across the continent. READ MORE :...

The UK's embattled prime minister is once again confronted by a domestic scandal involving his team, after trying to put the focus on policy while...

Military News

It goes a little something like this. 🎥 ➡️ National Guard About the U.S. Army: The Army Mission – our purpose – remains constant: To...

Extremely Powerful: US Air Force B-52H bombers showcase airpower in the Middle East Aircrews of U.S. Air Force B-52H "Stratofortress" strategic bombers assigned to the...

Sgt. 1st Class Dillon Dollar at Fort Benning has the answer! About the U.S. Army: The Army Mission – our purpose – remains constant: To...

Why the B 52 Is Such a Badass Plane? The Boeing B-52 Stratofortress is an aerial behemoth that has been a part of the US...

The First US Navy Littoral Combat Ship Operating in the Middle East USS Sioux City (LCS 11) landed in Bahrain on June 25 for a...

WASHINGTON (June 28, 2022) — Secretary of the Navy Carlos Del Toro delivers a message for Lesbian, Gay, Bisexual, Transgender, Queer (LGBTQ+) Pride Month. (U.S....

From getting off the bus to tackling the Rappel Tower, Basic Combat Training is full of firsts and once-in-a-lifetime experiences. About the U.S. Army: The...

Meet German Shepherds: One of the Best and Deadliest Military Dogs German Shepherds have all the qualities necessary for a military dog, making them the...

Building a force with diverse backgrounds, skills and experiences will ultimately enhance the Air Force and Space Force's ability to accomplish its mission. We are...

All rights reserved. © 2021 ACN NEWS
All Rights Reserved © ACN 2020

ACN Privacy Policies
ACN TOS
Area Control Network (ACN)
Area Control Network
Area Control Network Center